Recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (CD20, PD-L1)...
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
My Lymphoma has recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (CD20, PD-L1) available?
According to the NCCN Guidelines for Relapsed/Refractory Lymphoma (2023), treatment options depend on several factors, including:
- The specific type of lymphoma you have
- Time since your previous treatment
- Your overall health and ability to tolerate different therapies
- Results of biomarker testing
The Leukemia & Lymphoma Society (LLS) highlights several targeted therapy options based on biomarkers:
- For CD20-positive lymphomas: newer anti-CD20 antibodies like obinutuzumab
- For relapsed cases expressing PD-L1: checkpoint inhibitors like pembrolizumab
- CAR T-cell therapy for certain types of relapsed lymphoma
ASCO Guidelines (2023) recommend comprehensive biomarker testing at relapse because:
- Your lymphoma's biomarker status may have changed
- New targeted therapy options may have become available since your initial treatment
- This information helps determine the most effective treatment approach
It's essential to discuss with your healthcare team to:
- Get appropriate biomarker testing
- Review all available treatment options
- Consider clinical trial opportunities
Would you like me to provide more specific information about any particular treatment approach or biomarker? Please note that treatment recommendations should come from your healthcare team, as they understand your complete medical history.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Diffuse Large B-Cell Lymphoma (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Lymphoma patients
Have your records handy? Upload them for a deeper, personalized analysis →